The role of salvage cryoablation of the prostate for patients with clinically localized prostate cancer that have failed radiotherapy to the prostate is reviewed with reference to alternatives including salvage radical prostatectomy and brachytherapy. The diagnosis and workup of local recurrence/persistence of cancer in the prostate are reviewed and the patient selection criteria for salvage cryoablation is discussed. Technical aspects of the cryoablation procedure along with the outcome in terms of cancer control and treatment-related complications are detailed. The five-year biochemical disease-free rate is approximately 40%. The complication rate is acceptable. Salvage cryoablation definitely has a role in the management of localized prostate cancer treatment failure following radiotherapy, especially in older patients and those with some comorbidities.
Introduction
Radiation therapy as a primary treatment modality for prostate cancer has been successfully used for various stages of the disease. Patient factors influencing the ultimate success of radiation treatment include the prostate specific antigen (PSA) level, the biopsy Gleason grade, and the clinical stage. The 5 year PSA relapse-free rates range from 75 to 85% for the low risk group, 58 to 65% for the intermediate group, and 35 to 38% for the high risk group (1-3). Treatment parameters, influencing the ultimate success, include the modality of radiotherapy used, namely conventional (4) (5) (6) , 3D conformal (3), or intensity modulated conformal radiotherapy (7) . Selecting the correct modality should in turn allow for dose escalation, an independent predictive factor of success (1, 2, (8) (9) (10) . However, despite the relative success of external beam radiotherapy, a certain proportion of patients will fail systemically, locally or both. Local failure rates have varied between 25% and 32% (11) (12) (13) (14) .
Given the rate of local disease recurrence or persistence and its implication for eventual outcome (13, 15 ), a number of salvage treatment modalities have been appraised to determine whether salvage therapies with curative intent can be achieved in these patients. The main options in the salvage setting evaluated have been radical prostatectomy and cryosurgery, and more recently, brachytherapy. This article will concentrate on the role of salvage cryoablation in the management of patients who have demonstrated localized failure following definitive radiation therapy for prostate cancer.
Diagnosis of Local Recurrence
Maintaining a high index of clinical suspicion for the patient at risk for local failure after radiotherapy and increased vigilance in follow-up may help in diagnosing local failure. An advanced clinical stage has been found to be a predictor of local failure (11). Parameters which have been identified as predictors of local failure are PSA nadir (lowest level of serum PSA achieved after completion of radiotherapy) and PSA doubling time (PSA-DT). Patients achieving long-lasting biochemical control with undetectable PSA values are more likely to have PSA nadirs below 0.5 ng/ml (11, 16, 17) . In contrast, Crook et al. found that patients with local failures had a median nadir of 1.1 ng/ml and those with distant failure attained a median of 2.2 ng/ml (11). Sartor et al. found that a PSA nadir between 1 and 4 ng/ml was highly predictive of local failure (18). Patients with prostate cancer refractory to radiotherapy will demonstrate a progressive rise in serum PSA values following achievement of a PSA nadir. This rate of rise is likely to be more rapid in patients with distant failure (PSA-DT < 6 months) compared to those with local failure (PSA-DT > 6 months) (18).
The interpretation of a post radiotherapy biopsy should be made in the appropriate clinical context. Treatment effect can play an important role in the interpretation of biopsies after the tissue had been irradiated (11). Isolated positive biopsies after radiotherapy may not be indicative of local recurrence since a certain percentage of those patients may still eventually have negative biopsies when one allows for adequate time for the full radiotherapy effect. Conversely, caution has to be exercised when interpreting negative biopsies as the false negative rate has been shown to be as high as 19% (11).
Salvage Radical Prostatectomy
In 1985, Mador et al. reported the first series of radical prostatectomy and cystoprostatectomy with intent of salvaging patients who have failed radiotherapy (19). Since then, salvage surgery following radiation failure has been used with increasing relative success [5-year biochemical NED rates range between 55 and 69% (20-23)]. Certain series with longer follow-up have sustained results, with an 8-year biochemical NED rate of 33% (24) and 10 year rate of 43% (21). Clinical control, defined as failure to detect local recurrence or distant metastasis but with detectable PSA levels, ranges from 71 to 83% at 5 years (22) (23) (24) , and 61% at 10 years (21). Salvage prostatectomy may hence have a role in delaying disease progression in some very young, robust patients, even when cure appears less likely.
In terms of complications, radiation induced vasculitis, fibrosis and tissue plane obliteration have been factors leading to significant complications such as rectal injuries, anastomotic stricture, and urinary incontinence (24, 25) . The rate of rectal injury ranges between 0 and 19% compared with a rate of 1% in primary radical prostatectomy (26). The mean bladder neck contracture rate is 18% for all salvage prostatectomy series (27). As for incontinence, the mean rate for salvage radical prostatectomy is reported as approximately 45% (27, 28) . Other less frequent surgical complications include ureteral transection, fistulae, urinary extravasation, wound infections, and sepsis (21). Medical complications include deep vein thrombosis, pulmonary emboli, myocardial infarctions, and lymphedema (22). Thus, although there have been major improvements in the surgical techniques and amelioration of complication rates, radical prostatectomy remains a major challenging surgical undertaking with serious potential complications and is suitable only for patients who are relatively young and robust, devoid of significant comorbidities.
Salvage Brachytherapy
Brachytherapy has been reported as another potential salvage option for external radiation failure (29, 30) . The experience is very limited to two relatively small series The 5year biochemical NED rate reported were reported at 34% and 53%. Complications appeared significant but manageable. The role of salvage brachytherapy following external beam radiation failure needs to be elucidated with further experience and longer follow up.
Salvage Cryoablation of the Prostate
Cryoablation of the prostate (CabP) was first used in the 1960s but was quickly abandoned due to unacceptably high complication rates (31, 32) . It was reintroduced in 1988 by Onik et al. after improvements in percutaneous and cryogenic instrumentation as well as the introduction of transrectal ultrasonography for monitoring of the freezing process in real time (33). The initial enthusiasm for cryoablation of previously untreated prostate cancer waned when many centers failed to achieve sustained satisfactory biochemical outcome. The recent approval of cryoablation by the United States Centers for Medicare and Medicaid Services for use as first-line therapy in previously untreated prostate cancer has led to yet another resurgence in interest in primary cryoablation. The lack of evidence to date from randomized controlled clinical trials on CabP confirming its long-term efficacy, however, has led some groups, notably ours, to limit the use of CabP primarily to the salvage situation of tumor relapse after radiation therapy given with curative intent.
Patient Selection
All patients should have biochemical evidence of local treatment failure, i.e., rising PSA levels on 3 consecutive determinations at least 2 years after radical radiation therapy. All patients should be judged to have reasonable life-expectancy and acceptable anesthetic risks. All patients must have biopsy-proven local prostate cancer recurrence/persistence. Disease that is very advanced locally (T3B and T4) is not suitable for salvage cryoablation or are very large glands (> 60 grams) because of the significantly higher complication rate and inability to completely eradicate the cancerous organ. All patients should have negative pelvic and abdominal computerized tomography study as well as radionuclide bone scan. PSA levels should be < 20ng/dl (preferably < 5 ng/ml) at the time of consideration for CabP, to minimize the probability of occult distant metastatic disease. Patients with serum PSA levels between 10 and 20 ng/dl should have a negative pelvic lymphadenectomy or a negative CT-guided aspiration biopsy of pelvic nodes. Prior transurethral prostatectomy is a significant risk factor for incontinence and while it is not an absolute contraindication for CabP, the patients have to be counselled preoperatively of the distinct possibility of severe incontinence. Patients who have already undergone endocrine therapy and are demonstrating PSA levels, i.e., developing hormone resistance, have been shown to have poorer chance of success since they are more likely to have aggressive systemic disease, although they would not be categorically excluded from consideration for salvage cryoablation. Hormone therapy, however, is advisable as a pre-cryoablation neoadjuvant treatment to downsize the prostate if the gland-size exceeds 40 grams.
The Cryoablation Procedure
The first systems utilized liquid nitrogen as the cryogenic source. The liquid nitrogen tanks and the equipment were rather cumbersome. The second-generation units utilize pressurized argon gas as the cryogenic source, and helium for re-warming. The advantages of this system include more compact machinery and more rapid and efficient freezing. Five to six cryoprobes are usually used [sometimes up to 8 (34, 35) ] depending on the prostate size and configuration. The third generation cryosurgery units utilize a template originally designed for prostate cancer brachytherapy. The template allows introduction of up to 15 or 20 "needles" or small-caliber cryoprobes (17 gauge) delivered percutaneously through the template (36). This system produces multiple small "ice-seeds" instead of 5 or 6 "ice-balls". Experience is very limited with the new systems and although proponents suggest there maybe technical advantages over the larger-caliber probes, there may also be potential disadvantages and the verdict is still out.
Transrectal ultrasound systems are used for needle and probe guidance. Some centers have incorporated software for 3dimensional ultrasound into the system with the reported advantage of superior accuracy in probe placement and monitoring of the freezing process, thus minimizing treatmentrelated complications (37). A urethral warming device is used to minimize cryo-damage to the urethra. Three or more thermocouples are usually inserted into the peri-prostatic area for temperature monitoring. Some centers advocate more precise and complex temperature monitoring (38). One ancillary maneuver to minimize the risk of urethra-rectal fistula is the injection of saline into the pre-rectal potential space prior to the freezing procedure, to increase the distance between the rectal wall and the posterior prostate. This is achieved by insertion of a spinal needle into Denonvillier's fascia under transrectal ultrasound guidance.
Two, and sometimes three, freeze-thaw cycles are used in all cases as multiple cycles have been shown to have superior response compared to a single cycle (35, 36, 38) . The primary objective of prostate cryoablation is to eradicate all cancer tissue. Earlier preclinical studies have indicated several factors in maximizing the cytocidal effect including a double freeze, a rapid cooling rate, low end-temperature (between -20º and -40ºC) (39-41). Occasionally the probes are "pulled back" in the caudal direction prior to the second freeze, to accommodate a longer and larger prostate gland. A urethral foley catheter is employed for bladder drainage post-operatively. A trocar-type suprapubic cystostomy catheter is preferred by some and is usually left for drainage for up to two weeks in place of a urethral catheter.
Outcomes of Salvage Cryosurgery
There is no universal consensus on the definition of "success" with salvage cryoablation (42, 43) . The 5-year biochemical "no evidence of disease" (NED) rate for salvage cryosurgery was 40% in the M.D. Anderson series where failure was defined as a PSA of 2 ng/ml above nadir (37). Chin et al. reported a biochemical NED rate of 40% at 20 months with a definition of failure of any PSA > 0.5 ng/ml (42). However, the biochemical relapse free rates at 20 months improved to 62% and 73% when the treatment was defined as PSA > 2 ng/ml and > 4ng/ml respectively (42). Ghafar et al. obtained a "success" rate of 74% at 2 years with failure defined as 0.3 ng/ml above nadir (44). Whereas an undetectable PSA would be the optimal benchmark if one assumes that the prostate is completely ablated and no metastasis is present, it has been demonstrated that complete ablation is not usually attained. In fact, Chin et al. and Izawa et al. have identified, at two institutions, viable benign prostatic tissue in a substantial number of cryoablated prostates even when biopsies were negative for malignancy (42, 45) . Their findings suggest that since cryosurgery has limited capacity for complete prostate eradication, and thus legitimate concern exists regarding potential for future tumor recurrence. This, in turn, highlights the importance of vigilant coordinated pathological and biochemical follow-up in this patient population. Some pre-operative parameters (PSA levels, biopsy Gleason scores, and clinical stage) appear to correlate with biochemical outcome. Pre-cryotherapy PSA level <10 ng/ml and lower grade Gleason score (Gleason ≤ 8) are predictors of more favorable, sustained biochemical response (42, 44, 45) . Patients with lower preradiotherapy clinical stage (<T3) have better biochemical relapse-free rates (42, 43) . Patients who have received prior hormonal therapy in addition to radiotherapy, especially those who have already demonstrated rising PSA levels in spite of androgen suppression, appear to have a poorer outcome than those receiving radiotherapy alone (42, 47) . PSA nadir values post cryosurgery have been shown to be a positive predictor of long-term biochemical response (48).
The rate of local control reported for salvage cryosurgery exceeds that of biochemical control. The M.D. Anderson group performed biopsies at 6 months post cryosurgery and reported a positive biopsy rate of 23% (47). Miller et al. reported a positive biopsy rate of 37% on 33 patients at 3 months post-operatively with an 11-core biopsy technique (41). Chin et al. conducted serial biopsies on all salvage cryosurgery patients at 6, 12, 24 months postoperatively and thereafter as indicated by PSA levels. The positive biopsy rate was 14.2% (42). The majority of positive biopsies (73.9%) were reported within 1 year of cryoablation (36). The discrepancy in histological and the higher biochemical failure rates is problematic. One may suggest sampling errors in post-cryoablation biopsies although patients at some centers have had extensive regular follow-up biopsies (up to 6 sessions) with up to 30 cores (39). The other plausible explanation is the fact that a substantial number of these patients harbor occult metastatic disease at the time of their salvage CabP in spite of diligent metastatic work-up. These patients, despite successful local eradication of the cancer, subsequently manifest biochemical failure.
Utility of Salvage Cryoablation
As mentioned, a significant proportion of patients undergoing cryoablation eventually develop biochemical failure. These patients will usually go on to receive endocrine therapy. Even if these patients do not achieve a cure with salvage cryoablation, the onset of endocrine therapy has been deferred, usually for several years. This confers a significant benefit as the patients have been spared the side effects of hormone therapy and the inevitable development of hormone resistance of prostate cancer has been deferred accordingly.
Complications of Salvage Cryosurgery
In general, the complication rates of salvage cryosurgery are higher than those of primary cryosurgery. Taking into account variations in definitions employed at different centers, the rate of certain complications has declined over the years with improvement in technology and in techniques (40, 42, (44) (45) (46) (47) (48) (49) (50) (51) (52) .
Recto-urethral fistula is one of the most serious complications. The rate is generally reported to be between 0 and 3% (31, 34, (41) (42) (43) (44) (45) with one series reporting an 11% rate (45). This underscores the importance of accurate probe placement and real time treatment monitoring. Chin et al. have used intraoperative 3-dimensional ultrasound to facilitate this process (37). The rate of incontinence varies with the definition used and whether it is patient-reported or physicianassessed. The rate ranges widely from 9% (50) to 83% (51). The incontinence improves with time. Using an appropriate urethral warming device helps to alleviate the incontinence rate (53). The risk of incontinence increases exponentially if the patient has had prior transurethral resection of the prostate or bladder neck (and the patients should be forewarned accordingly). In general, complication rates and severity closely correlate with duration and extent of freezing. The larger the area and the longer the freezing duration, the more collateral damage to adjacent anatomical structures might be expected. It is important to note, however, that less extensive freezing and fewer complications may come at the expense of less complete prostate ablation. Chin et al. found that local recurrence at the apex is more frequent than other locations due to attempted sparing of the urethral sphincter (54).
Conclusions
There appears to be a role for salvage cryoablation in patients who have localized persistent disease following radiation therapy for prostate cancer, depending on the patient's age, performance status, and comorbidities. While salvage radical prostatectomy is usually reserved for younger patients with few medical comorbidities, salvage cryoablation is a viable alternative especially in older patients and those with some comorbidities, but with an acceptable operative risk. Biochemical NED rates in cryosurgery have varied according to the definition of biochemical failure. Five-year biochemical NED is in the range of 40%. Complications of salvage cryoablation are acceptable.
